Life sciences,raised properly
Clinical, regulatory and reimbursement risk explained in one sequence a committee can underwrite.
What is different about raising in life sciences
Investors underwrite the pathway before the science: indication, endpoint, regulatory route and what the next readout proves.
Cash to next value inflection is the number that decides the round size.
Reimbursement and payer strategy is increasingly diligenced at Series A, not Series C.
The engine behind the raise
Capital types we most often work across here: Venture capital, Strategic and corporate, Grant matched equity.
- Development plan mapped to capital required per milestone and cash to next readout
- Regulatory and IP pack assembled ahead of diligence
- Investor audience across specialist funds, family offices and strategic co-investors
- Investment memorandum that keeps the science accurate and the case legible
- Financial promotion perimeter check on every investor-facing asset
The questions capital will ask
If you cannot answer these with evidence in the data room, the process stalls at week two.
- Which indication, which endpoint, and what does the next readout prove?
- What is the regulatory route, and has it been agreed with the regulator?
- How much cash to the next value inflection, and what is the burn today?
- What is the IP position and remaining patent life?
We work across private markets
Fintech
Payments, lending, wealth infrastructure and embedded finance, raised with materials that survive a diligence team who already knows the sector.
View sectorDeeptech
Hard science, long horizons and technical risk, presented so a generalist committee can underwrite what a specialist already understands.
View sectorTechnology and software
SaaS, marketplaces and platforms, raised on metrics that reconcile to the accounts rather than to a slide.
View sectorBiotech
Platform or asset, preclinical or clinical, the raise gets built around what the next milestone proves and what it costs.
View sectorHealthtech
Digital health and care technology, raised on adoption evidence, procurement reality and a credible route to contracted revenue.
View sectorEngineering and industrials
Manufacturing, advanced engineering and industrial businesses, raised on order book, capacity and the capex plan behind them.
View sectorCleantech and energy transition
Where technology risk meets project risk, raised with the structure, offtake and permitting position resolved before outreach begins.
View sectorInfrastructure projects
Shovel-ready or nearly there, raised on planning, permits, offtake and a contracting structure that stands up to lender diligence.
View sectorReal estate
Development and income strategies, raised on site control, planning status, debt position and a stated exit.
View sectorPrivate credit
Borrowers and sponsors raising private debt, presented with the security package, coverage and covenant position resolved up front.
View sectorSustainable Wealth Group is not authorised or regulated by the Financial Conduct Authority. Nothing on this page is advice, or an invitation or inducement to engage in investment activity. Capital at risk.